Get started
Work

130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor

Year: 2022
Type: article
Study design: Clinical Trial
Abstract: Novel agents are urgently needed for the treatment [tx] of patients [pts] with metastatic NSCLC including post immune checkpoint inhibitors (ICI). COM701 [anti-PVRIG] is a novel 1st in class ICI. We hypothesized that COM701 ± nivolumab will demonstrate antitumor activity with a favorable safety and tolerability profile in pts with heavily pretreated NSCLC. Here, we present preliminary results on antitumor activity.
DOI: 10.1016/j.iotech.2022.100242
Authors: R.J. Sullivan, M.R. Sharma, D. Vaena, E. Hamilton, B. Izar, D. Rasco, J. Gainor, D. Shepard, K. Papadopoulos, E.E. Dumbrava, H.H. Adewoye, P.J. Ferre, E. Ophir, M. Patel, A. Patnaik, B. Chmielowski
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W4310923740
FWCI:
Cites:
Cited by:
Related to: 10